Baird Downgrades Frequency Therapeutics to Neutral, Lowers Price Target to $0.5
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen has downgraded Frequency Therapeutics (NASDAQ:FREQ) from Outperform to Neutral and lowered the price target from $4 to $0.5.
September 26, 2023 | 8:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Frequency Therapeutics has been downgraded by Baird from Outperform to Neutral, with a lowered price target from $4 to $0.5.
The downgrade from Outperform to Neutral by Baird, coupled with a significant reduction in the price target from $4 to $0.5, indicates a less optimistic outlook for Frequency Therapeutics. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100